At the request of the U.S. Food and Drug Administration, U.S. Marshals seized drug products from Global Biotechnologies of Portland, Maine in late May.
According to the complaint, Global Biotechnologies has made claims on its website, in promotional materials and on the products' labels that its products can diagnose, cure, mitigate, treat or prevent human diseases. However, the company failed to provide adequate directions for use for its drug products, causing those products to be misbranded drugs in violation of the Federal Food, Drug and Cosmetic Act.
The FDA sent a warning letter to Global Biotechnologies, but the company had continued to make illegal claims that cause their products to be misbranded drugs. The company's products include Glucanol, Healthy Trac, Immunol and Lactopril.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
According to the complaint, Global Biotechnologies has made claims on its website, in promotional materials and on the products' labels that its products can diagnose, cure, mitigate, treat or prevent human diseases. However, the company failed to provide adequate directions for use for its drug products, causing those products to be misbranded drugs in violation of the Federal Food, Drug and Cosmetic Act.
The FDA sent a warning letter to Global Biotechnologies, but the company had continued to make illegal claims that cause their products to be misbranded drugs. The company's products include Glucanol, Healthy Trac, Immunol and Lactopril.
Related Articles on Medication Safety:
3 Independent Risk Factors Associated With Medication Errors
Public, Positive Recognition Boosts Compliance to Medication Reconciliation
Drug Recalls Frequent But Not Always Publicized
